The mission of the Division of Psychiatric Genomics is to apply genetic insights to the clinical practice of psychiatry. Ours is a molecular, genomic, and translational focus. We aim to break down barriers to collaboration through support of highly interdisciplinary research.
Psychiatric disease remains a relatively uncharted frontier in medicine. The major psychiatric diseases affect a significant proportion of Americans, and the costs in terms of lost years of productivity are enormous for patients and their families.
Researchers across the Mount Sinai Health System are making progress in understanding the genetic architecture of many conditions. Our work in the Division of Psychiatric Genomics has three major areas of focus that are critical to progress in the future:
- Genetics and genomics
- Molecular translational laboratories, including a focus on plasticity, neurodevelopment, and neural stem cells
- Clinical trials
Our division goal is to shape future treatment of psychiatric patients using the tools of modern genomics to understand biological bases and risks of developing psychiatric disease.
Genetics and Genomics
Today, large-scale genomic studies are detecting genes linked to several psychiatric diseases including autism, bipolar disorder, and schizophrenia. Our researchers are leading initiatives to obtain genomic sequence data from thousands of affected individuals with these illnesses, which will increase the number of genes we find to examine. This is proving to be a highly complex genetic landscape, and we need to reexamine existing approaches that model changes in multiple, intricate ways.